Church & Dwight Co. Earnings Call Transcripts
Fiscal Year 2026
-
Consistent organic growth is driven by innovation, strategic acquisitions, and a balanced brand portfolio. Key initiatives target expansion of Arm & Hammer, TheraBreath, and international business, with strong financial performance and a focus on AI to enhance efficiency.
-
Q1 2026 saw strong organic sales growth of 5% and adjusted EPS up 4.4% year-over-year, driven by volume and innovation. Full-year guidance for organic growth (3%-4%) and EPS (5%-8%) was reiterated despite inflationary pressures from the Middle East.
-
Consistent category outperformance, portfolio reshaping, and innovation fueled strong growth in 2025, with key brands like ARM & HAMMER, TheraBreath, and Hero driving share gains. The 2026 outlook targets 3%-4% organic growth, 100 bps margin improvement, and 5%-8% EPS growth, supported by disciplined capital allocation and focused growth initiatives.
Fiscal Year 2025
-
Q4 and FY2025 results exceeded expectations with strong sales, margin, and EPS growth, driven by power brands and portfolio reshaping. 2026 guidance calls for 3%-4% organic growth, 100 bps margin expansion, and continued investment in innovation and international expansion.
-
Q3 results exceeded expectations with 3.4% organic sales growth and strong EPS. Touchland acquisition outperformed, while value and premium brands drove share gains. Full-year guidance was raised for sales, EPS, and cash flow, with continued focus on M&A and innovation.
-
Confidence in future growth is driven by strong brand performance, innovation, and expanding international and e-commerce channels. Key brands like Arm & Hammer, Hero, and TheraBreath are gaining share, while new acquisitions and product launches fuel momentum. 2025 guidance targets up to 2% sales and EPS growth.
-
Organic sales and adjusted EPS exceeded expectations in Q2, driven by share gains in key brands and improved category consumption. The company closed the Touchland acquisition, exited several businesses, and is reviewing strategic options for its vitamin segment, while maintaining a cautious outlook amid ongoing macro volatility.
-
ARM & HAMMER and other power brands continue to gain share through innovation and a strong multi-category presence, with recent acquisitions like Touchland expected to drive further growth. International expansion, disciplined M&A, and robust online and specialty product performance support a positive 2025 outlook.
-
The acquisition of a leading, fast-growing hand sanitizer brand for up to $880 million is expected to be EPS-neutral in 2025 and 3% accretive to cash earnings in 2026. The deal leverages innovation, strong brand loyalty, and international expansion, with a focus on premium channels and significant runway for growth.
-
Organic sales declined 1.2% in Q1 2025, with adjusted EPS down 5.2% year-over-year but slightly above guidance. The outlook for full-year organic growth and EPS was lowered due to weak U.S. consumer demand, retail destocking, and tariff impacts, while portfolio pruning and supply chain actions are expected to significantly reduce tariff exposure.
-
Leadership transition is underway as the company reports strong 2024 results, with 4.5% organic growth, robust cash flow, and five of seven power brands gaining share. Innovation and international expansion remain key priorities, supported by a disciplined M&A strategy and a focus on digital transformation.
Fiscal Year 2024
-
2024 delivered strong organic growth, margin expansion, and robust cash flow, driven by innovation and international momentum. 2025 guidance targets 3%-4% organic growth, 25 bps margin expansion, and 7%-8% EPS growth, with continued focus on M&A and digital leadership.
-
Q3 saw strong organic sales and EPS growth, driven by volume and innovation across key brands. A $357M impairment hit the vitamin business, but international and specialty segments posted robust gains. Cautious Q4 guidance reflects category volatility and increased promotional activity.
-
Management outlined a strategy focused on 4% organic growth, innovation, and disciplined acquisitions, supported by strong brands and expanding e-commerce. Financial targets include 8-9% EPS growth and robust cash flow, with capital prioritized for M&A. International expansion and operational efficiency remain key priorities.
-
Q2 delivered strong sales and EPS beats, with robust gross margin expansion and market share gains across most brands. Full-year guidance was tightened due to category deceleration, but innovation and international growth remain key strengths.
-
The company projects strong 2024 growth, driven by innovation, e-commerce, and disciplined M&A. U.S. and international businesses are both expanding, with key brands like TheraBreath and Hero gaining share. Focus areas include sustainability, digital marketing, and asset-light operations.